News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
HUMPHREY RACHEL
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/15/2022 |
4
| HUMPHREY RACHEL (Director) has filed a Form 4 on Pyxis Oncology, Inc.|
Txns:
| Granted 236,220 options to buy
@ $2.91, valued at
$687.4k
|
|
| 08/15/2022 |
3
| HUMPHREY RACHEL (Director) has filed a Form 3 on Pyxis Oncology, Inc. |
| 10/21/2021 |
3
| HUMPHREY RACHEL (Director) has filed a Form 3 on Xilio Therapeutics, Inc. |
| 02/19/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/10/2020 |
4
| HUMPHREY RACHEL (Chief Medical Officer) has filed a Form 4 on Black Diamond Therapeutics, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Granted 150,000 options to buy
@ $28.14, valued at
$4.2M
|
|
| 09/10/2020 |
3
| HUMPHREY RACHEL (Chief Medical Officer) has filed a Form 3 on Black Diamond Therapeutics, Inc. |
| 01/29/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/05/2018 |
4
| HUMPHREY RACHEL (Chief Medical Officer) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Sold 16,160 shares
@ $30, valued at
$484.8k
Exercised 16,160 options to buy
@ $6.6147, valued at
$106.9k
|
|
| 03/02/2018 |
4
| HUMPHREY RACHEL (Chief Medical Officer) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Sold 23,840 shares
@ $30, valued at
$715.2k
Exercised 23,840 options to buy
@ $6.6147, valued at
$157.7k
|
|
| 01/26/2018 |
4
| HUMPHREY RACHEL (Chief Medical Officer) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $25.82, valued at
$2.6M
|
|
| 12/19/2017 |
4
| HUMPHREY RACHEL (Chief Medical Officer) has filed a Form 4 on CytomX Therapeutics, Inc.|
Txns:
| Exercised 15,117 options to buy
@ $6.6147, valued at
$100k
|
|
| 01/27/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 12/29/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|